Literature DB >> 25879630

Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir.

Jesper F Højen1, Thomas A Rasmussen1, Karen Lise D Andersen1, Anni A Winckelmann1, Rune R Laursen1, Jesper D Gunst1, Holger J Møller2, Mayumi Fujita3, Lars Østergaard1, Ole S Søgaard1, Charles A Dinarello4,5, Martin Tolstrup1.   

Abstract

Interleukin-37 (IL-37) is a recently identified cytokine with potent antiinflammatory and immunosuppressive functions. The objective of this study was to compare levels of IL-37 mRNA in immunological subgroups of chronic human immunodeficiency virus-1 (HIV-1)-infected individuals and noninfected controls, to determine IL-37's association with biomarkers of inflammation and reservoir size. This was a cross-sectional study. The HIV-1-infected patients were categorized in three subgroups depending on their combination antiretroviral therapy (cART) treatment status and CD4(+) T-cell count. Quantitative RT-PCR was used for the detection of IL-37 mRNA and HIV-1 DNA in peripheral blood mononuclear cells (PBMCs). Biomarkers in plasma were quantified by enzyme-linked immunosorbent assay (ELISA), whereas T-cell activation was determined by flow cytometry. Lastly, lipopolysaccharide (LPS) stimulations of patients PBMCs were carried out to determine differences in IL-37 mRNA response between the subgroups. Sixty HIV-1-infected patients and 20 noninfected controls were included in the study. Steady-state IL-37 mRNA levels in PBMCs were significantly higher in HIV-1-infected individuals compared with noninfected controls: 2.4-fold (p ≤ 0.01) cART-naïve subjects; 3.9-fold (p ≤ 0.0001) inadequate immunological responders; and 4.0-fold (p ≤ 0.0001) in immunological responders compared with non-infected controls. Additionally, levels of the monocyte inflammatory marker sCD14 correlated with IL-37 mRNA (p = 0.03), whereas there was no association with T-cell activation. Finally, we observed a significant correlation between total viral HIV-1 DNA and IL-37 mRNA in PBMCs (p < 0.0001). Collectively, our data shows that the level of IL-37 mRNA is affected by chronic HIV-1-infection. A relationship with the activation of the monocyte compartment is suggested by the correlation with sCD14 and, interestingly, IL-37 could be related to the size of the total viral HIV-1 reservoir.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25879630      PMCID: PMC4534469          DOI: 10.2119/molmed.2015.00031

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  58 in total

1.  Four new members expand the interleukin-1 superfamily.

Authors:  D E Smith; B R Renshaw; R R Ketchem; M Kubin; K E Garka; J E Sims
Journal:  J Biol Chem       Date:  2000-01-14       Impact factor: 5.157

2.  Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.

Authors:  Gilbert R Kaufmann; Hansjakob Furrer; Bruno Ledergerber; Luc Perrin; Milos Opravil; Pietro Vernazza; Matthias Cavassini; Enos Bernasconi; Martin Rickenbach; Bernard Hirschel; Manuel Battegay
Journal:  Clin Infect Dis       Date:  2005-06-24       Impact factor: 9.079

3.  Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.

Authors:  Josep M Llibre; Maria J Buzón; Marta Massanella; Anna Esteve; Viktor Dahl; Maria C Puertas; Pere Domingo; Josep M Gatell; Maria Larrouse; Mar Gutierrez; Sarah Palmer; Mario Stevenson; Julià Blanco; Javier Martinez-Picado; Bonaventura Clotet
Journal:  Antivir Ther       Date:  2011-09-28

4.  Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events.

Authors:  E Lien; P Aukrust; A Sundan; F Müller; S S Frøland; T Espevik
Journal:  Blood       Date:  1998-09-15       Impact factor: 22.113

5.  Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy.

Authors:  Stefania Piconi; Daria Trabattoni; Andrea Gori; Serena Parisotto; Carlo Magni; Paola Meraviglia; Alessandra Bandera; Amedeo Capetti; Giuliano Rizzardini; Mario Clerici
Journal:  AIDS       Date:  2010-08-24       Impact factor: 4.177

6.  IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp.

Authors:  G Pan; P Risser; W Mao; D T Baldwin; A W Zhong; E Filvaroff; D Yansura; L Lewis; C Eigenbrot; W J Henzel; R Vandlen
Journal:  Cytokine       Date:  2001-01-07       Impact factor: 3.861

7.  Plasma levels of soluble CD14 independently predict mortality in HIV infection.

Authors:  Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek
Journal:  J Infect Dis       Date:  2011-01-20       Impact factor: 5.226

Review 8.  Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions.

Authors:  Julie C Gaardbo; Hans J Hartling; Jan Gerstoft; Susanne D Nielsen
Journal:  Clin Dev Immunol       Date:  2012-03-14

9.  Protective host defense against disseminated candidiasis is impaired in mice expressing human interleukin-37.

Authors:  Frank L van de Veerdonk; Mark S Gresnigt; Marije Oosting; Jos W M van der Meer; Leo A B Joosten; Mihai G Netea; Charles A Dinarello
Journal:  Front Microbiol       Date:  2015-01-07       Impact factor: 5.640

10.  HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.

Authors:  Maud Mavigner; Pierre Delobel; Michelle Cazabat; Martine Dubois; Fatima-Ezzahra L'faqihi-Olive; Stéphanie Raymond; Christophe Pasquier; Bruno Marchou; Patrice Massip; Jacques Izopet
Journal:  PLoS One       Date:  2009-10-30       Impact factor: 3.240

View more
  14 in total

1.  Development and characterization of monoclonal antibody against human IL-37b.

Authors:  Yu-Chi Gao; Yan Jia; De-Qian Xiao; Xin Wang; You-Chao Dai; Shi-Yan Yu; Chen Chen; Ze-Gang Zhuang; Xiao-Xia Fu; Jun-Ai Zhang; Bi-Ying Zheng; Zhi-Hong Chen; Ji-Xin Zhong; Zhang-Quan Chen; Jun-Fa Xu
Journal:  Cytotechnology       Date:  2017-02-18       Impact factor: 2.058

Review 2.  Interleukin 30 to Interleukin 40.

Authors:  Jovani Catalan-Dibene; Laura L McIntyre; Albert Zlotnik
Journal:  J Interferon Cytokine Res       Date:  2018-10       Impact factor: 2.607

3.  Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment.

Authors:  Saverio G Parisi; Samantha Andreis; Carlo Mengoli; Nicola Menegotto; Silvia Cavinato; Renzo Scaggiante; Massimo Andreoni; Giorgio Palù; Monica Basso; Anna Maria Cattelan
Journal:  Med Microbiol Immunol       Date:  2018-03-09       Impact factor: 3.402

Review 4.  The Role of IL-37 in Non-Cancerous Diseases.

Authors:  Vivi A Ding; Ziwen Zhu; Alyse A Mantz; Huaping Xiao; Mark R Wakefield; Qian Bai; Yujiang Fang
Journal:  Pathol Oncol Res       Date:  2016-10-27       Impact factor: 3.201

5.  Interleukin-37: A crucial cytokine with multiple roles in disease and potentially clinical therapy.

Authors:  Lijuan Wang; Yanchun Quan; Yongfang Yue; Xueyuan Heng; Fengyuan Che
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967

Review 6.  Residual inflammation and viral reservoirs: alliance against an HIV cure.

Authors:  Marta Massanella; Rémi Fromentin; Nicolas Chomont
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

Review 7.  Suppression of innate inflammation and immunity by interleukin-37.

Authors:  Charles A Dinarello; Claudia Nold-Petry; Marcel Nold; Mayumi Fujita; Suzhao Li; Soohyun Kim; Philip Bufler
Journal:  Eur J Immunol       Date:  2016-05       Impact factor: 5.532

8.  Tuberculosis-sensitized monocytes sustain immune response of interleukin-37.

Authors:  Jun-Ai Zhang; Gan-Bin Liu; Bi-Ying Zheng; Yuan-Bin Lu; Yu-Chi Gao; Xiao-Zhen Cai; You-Chao Dai; Shi-Yan Yu; Yan Jia; Chen Chen; Ze-Gang Zhuang; Xin Wang; Wan-Dang Wang; Xiao-Xia Fu; Lai-Long Yi; Ling Shen; Zheng W Chen; Jun-Fa Xu
Journal:  Mol Immunol       Date:  2016-09-29       Impact factor: 4.407

Review 9.  Overview of the IL-1 family in innate inflammation and acquired immunity.

Authors:  Charles A Dinarello
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

Review 10.  Potential role of IL-37 in atherosclerosis.

Authors:  Sara McCurdy; Chloe A Liu; Jonathan Yap; William A Boisvert
Journal:  Cytokine       Date:  2017-10-05       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.